Definium Therapeutics (DFTX) Net Income towards Common Stockholders (2021 - 2026)
Definium Therapeutics (DFTX) posted quarterly Net Income towards Common Stockholders of -$77.1 million for Q1 2026, down 230.21% year-over-year from $59.2 million in Q1 2025, and down 52.86% quarter-over-quarter from -$50.4 million in Q4 2025.
Powered by 
Analysis
Definium Therapeutics (DFTX) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Net Income towards Common Stockholders for 6 consecutive years, with -$77.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 230.21% year-over-year to -$77.1 million; the TTM figure through Mar 2026 stood at -$237.5 million (down 206.01% YoY), while the FY2025 annual figure was -$183.8 million, down 69.12% from the prior year.
- Net Income towards Common Stockholders eased to -$77.1 million in Q1 2026 per DFTX's latest filing, from -$50.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$5.1 million in Q4 2022 and bottomed at -$77.1 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$31.0 million across 5 years, with a median of -$23.3 million in 2025.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders soared 79.0% — and 2025, when it sank 630.17%.
- Definium Therapeutics' Net Income towards Common Stockholders stood at -$5.1 million in 2022, then slumped by 322.88% to -$21.7 million in 2023, then plunged by 60.24% to -$34.7 million in 2024, then tumbled by 45.18% to -$50.4 million in 2025, then plunged by 52.86% to -$77.1 million in 2026.
- Business Quant data shows DFTX's Net Income towards Common Stockholders at -$77.1 million in Q1 2026, -$50.4 million in Q4 2025, and -$67.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Definium Therapeutics | 4.23 Bn | 4.23 Bn | - | -158.99 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -158.99 Mn |
| Mar 31, 2026 | -77.10 Mn |
| Dec 31, 2025 | -50.44 Mn |
| Sep 30, 2025 | -67.27 Mn |
| Jun 30, 2025 | -42.74 Mn |
| Mar 31, 2025 | -23.35 Mn |
| Dec 31, 2024 | -34.74 Mn |
| Sep 30, 2024 | -13.68 Mn |
| Jun 30, 2024 | -5.85 Mn |
| Mar 31, 2024 | -54.40 Mn |
| Dec 31, 2023 | -21.30 Mn |
| Sep 30, 2023 | -20.45 Mn |
| Jun 30, 2023 | -27.87 Mn |
| Mar 31, 2023 | -19.58 Mn |
| Dec 31, 2022 | 2.06 Mn |
| Sep 30, 2022 | -16.49 Mn |
| Jun 30, 2022 | -16.96 Mn |
| Mar 31, 2022 | -18.51 Mn |
| Dec 31, 2021 | 1.80 Mn |
| Sep 30, 2021 | -17.20 Mn |